Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioAge Labs, Inc. - Common Stock (NQ:BIOA)

4.760 +0.050 (+1.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioAge Labs, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Levi & Korsinsky Reminds Shareholders of an Investigation into BioAge Labs, Inc. (BIOA) Regarding Potential Securities Fraud Allegations
Via ACCESSWIRE
Shareholders that lost money on BioAge Labs, Inc. (BIOA) should contact Levi & Korsinsky about Securities Fraud Investigation - BIOA
Via ACCESSWIRE
Investors who lost money on BioAge Labs, Inc. should contact Levi & Korsinsky about an ongoing investigation - BIOA
Via ACCESSWIRE
ATTENTION BIOA SHAREHOLDERS: Investors who lost money on BioAge Labs, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Via ACCESSWIRE
BioAge Labs Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Encourages Shareholder Participation
Via ACCESSWIRE
Levi & Korsinsky Reminds Shareholders of an Investigation into BioAge Labs, Inc. (BIOA) Regarding Potential Securities Fraud Allegations
Via ACCESSWIRE
BioAge Labs, Inc. Being Investigated on Behalf of BioAge Labs, Inc. Investors. Contact Levi & Korsinsky For Details
Via ACCESSWIRE
Levi & Korsinsky Announces an Investigation on Behalf of BioAge Labs, Inc. (BIOA) Shareholders Who May Have Been Affected by Fraud
Via ACCESSWIRE
BIOA Investors Have Opportunity to Join BioAge Labs, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Crude Oil Gains 2%; BioAge Labs Shares Plunge
 
Via Benzinga
Nasdaq Down Over 100 Points; US Wholesale Inventories Rise By 0.2%
 
Via Benzinga
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates expected in Q1 2025. 
Via Benzinga
Topics Initial Public Offering
Why Interpublic Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
Two presentations to highlight increased weight loss in obese mice treated with azelaprag in combination with multiple oral appetite suppressants, and significant protection against weight gain with... 
From BioAge Labs, Inc.
Via GlobeNewswire
BioAge Labs to Present at Jefferies London Healthcare Conference
From BioAge Labs, Inc.
Via GlobeNewswire
Self-Driving Startup Pony.ai Files For U.S. IPO
Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group... 
Via Talk Markets
Topics Initial Public Offering
Prediction: These 2 Stocks Could Soar in 2025
The key word here is "could." 
Via The Motley Fool
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs. 
Via The Motley Fool
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm. 
Via The Motley Fool
Topics Initial Public Offering
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
One of these businesses is a risky play, but the other is very likely to succeed. 
Via The Motley Fool
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October
There's a chance that its lead candidate could become one of the top drugs ever. 
Via The Motley Fool
This IPO Biotech Stock Could Be the Next Eli Lilly
BioAge has its eyes on a handful of truly gargantuan markets. 
Via The Motley Fool
Topics Initial Public Offering
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
From BioAge Labs, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.